Avem Health Partners, Inc (FPCG) Fair Value & Analysis
Healthcare · US · Market cap $10.1M
Avem Health Partners, Inc
FPCG · US
Fair value as of: Jul 16, 2026
From 23 valuation models · updated today
Fair value updated Jul 16, 2026 — revised from $9,714 to $1,239 (−87.2%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $1,025 – $1,025 · fair‑value band $813.00 – $1,786 · the $1,025 price screens below the $1,239 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Avem Health Partners, Inc (FPCG) currently trades at $1,025, while our model-based Fair Value estimate is $1,239 — implying the stock looks roughly 20.9% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Avem Health Partners, Inc generated revenue of $23.1M at a net margin of 38.8%. Revenue grew 32.1% year over year. It earns a return on equity of 68.9%. The stock trades on a trailing P/E of 0.1. Fundamentals as of Jul 16, 2026
Our scenario range runs from $813.00 (bear case) to $1,786 (bull case); at $1,025, the current price sits within that range. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -18% fair-value upside — at 21%, FPCG screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Avem Health Partners, Inc. provides financial, technology, management, and capital solutions to hospitals in rural markets. Its services benefit residents and their physicians, as well as help to sustain and preserve the quality of healthcare services in these communities. The company was founded in 1980 and is headquartered in Oklahoma City, Oklahoma.
Revenue & earnings trend
FY2009 – FY2013 · reported fiscal years
Avem Health Partners, Inc reported revenue of $19.4M in FY2013 versus $39.1M in FY2009, a compound −16.1%/yr. Reported net income was $5.8M in FY2013.
Is FPCG fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,469 | ₹2,967 | -65% |
| Fresenius Medical Care AG FMS | $23.39 | $45.83 | +96% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥6.73 | -18% |
| Bangkok Dusit Medical Services Public Company BDUUF | $0.6400 | $0.4600 | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Avem Health Partners, Inc (FPCG) undervalued?
What is the fair value of FPCG?
What is the quality score of FPCG?
What is the revenue of Avem Health Partners, Inc (FPCG)?
What is the net profit margin of FPCG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when Avem Health Partners, Inc reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of Avem Health Partners, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.